Glioma News and Research

RSS

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).

Study explains how stroke promotes aggressive glioma tumor growth

Researchers at Texas Children's Duncan Neurological Research Institute (Duncan NRI), Baylor College of Medicine and collaborating institutions show in Nature Cancer that stroke promotes glioma growth and uncovered cellular and molecular mediators involved in the process, linking brain injury to malignant brain tumors.

25 Sep 2026

Engineered nanoparticles sensitize gliomas to radiotherapy

Gliomas are a major cause of cancer-related deaths in younger adults.

24 Sep 2026

Scientists discover metabolite fueling aggressive brain tumor growth

Virtually all high-grade, aggressive gliomas in adults accumulate massive amounts of a metabolite called guanidinoacetate (GAA) that overstimulates nearby neurons and promotes tumor growth, according to new research from scientists at Children’s Medical Center Research Institute at UT Southwestern (CRI) published in Cell.

18 Sep 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

Aging brain actively shapes biology and progression of tumors

Brain tumors develop within an organ that changes substantially with age. A new review in Ageing and Cancer Research & Treatment examines evidence that the aging brain microenvironment may influence brain tumor progression, treatment resistance, and cognitive outcomes.

10 Sep 2026

Vitamin A derivative prevents immune cell exhaustion in brain tumors

Immune cells can become exhausted after prolonged exposure to cancer, gradually losing their ability to attack tumor cells.

8 Sep 2026

Inhibitory neurons act as a brake on brain tumor growth

Brain tumors do not grow in isolation. They develop within the highly active environment of the brain, where neurons continuously exchange electrical and chemical signals.

7 Sep 2026

Mount Sinai researchers discover new radiation option for childhood brain cancer

Children with one of the deadliest forms of brain cancer may benefit from an additional course of radiation therapy after their disease returns, according to new research from the Icahn School of Medicine at Mount Sinai.

2 Sep 2026

Study reveals why diffuse midline glioma develops in brain midline regions

Scientists at St. Jude Children's Research Hospital have shown that specific brain cells respond differently to the H3.3 K27M, a mutation in the histone H3.3 protein that drives many cases of diffuse midline glioma (DMG), depending on the cell's location in the developing brain.

27 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

AI model predicts cancer subtype, genetic mutations, and survival outcomes across 32 solid tumors

Researchers have developed a novel AI model that can analyze a routine whole histopathology image and simultaneously predict cancer subtype, specific genetic mutations, and survival outcomes across 32 different solid cancers rather than focusing on a single cancer type.

13 Aug 2026

Scientists combine imaging and phototherapy in a single tool against glioblastoma

Glioblastoma is the most aggressive form of brain cancer.

6 Aug 2026

Obscure X chromosome protein emerges as key driver in several cancers

A little-known protein encoded on the X chromosome is attracting growing attention for its potential role in cancer development and treatment.

5 Aug 2026

New AI-based method could improve detection and classification of brain tumors from MRI scans

Researchers have developed a new artificial intelligence-based method that could significantly improve the detection and classification of brain tumors from MRI scans, achieving higher accuracy than conventional diagnostic systems.

29 Jul 2026

KAIST study opens a new avenue for treating intractable brain tumors

Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune "brakes" exploited by tumors to evade attack-show limited efficacy in some brain tumors.

19 Jul 2026

Multimodal surgery improves outcomes for rare corpus callosum glioma

Brain tumor surgeries are particularly challenging due to the difficult trade-off neurosurgeons often face—remove more tumor and risk neurological injury, or preserve function and leave more tumor behind.

17 Jul 2026

New study explains how brain tumors evolve to resist treatment

A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.

11 Jul 2026

Study potential new therapeutic strategy for patients with ATRX-mutant gliomas

A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common genetic alterations in glioma rewires the cancer cell genome to fuel tumor progression, suggesting a potential new therapeutic strategy for patients with ATRX-mutant gliomas.

1 Jul 2026

First-in-human trial tests safer T-cell therapy for pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors.

30 Jun 2026

FluoGuide announces positive results from Phase 2 oral head and neck cancer trial

FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer.

30 Jun 2026